
ZBH Stock Forecast & Price Target
ZBH Analyst Ratings
Bulls say
Zimmer Biomet Holdings is projected to achieve 2025 sales of $7.85 billion, reflecting a 4.0% year-over-year increase when excluding foreign exchange impacts, alongside an adjusted EPS of $8.23, indicating a growth of 2.9% year-over-year. Despite losing some global reconstructive market share, the company's strategic focus on new product launches in the knee and hip segments, particularly in their Persona portfolio and ROSA technology, is expected to bolster its market position and enhance revenue growth in high-potential areas. Additionally, the anticipated operational margin expansion from the ZimVie spin-off is likely to support Zimmer Biomet’s goal of averaging a 30 basis point increase in operational margin annually.
Bears say
The analysis indicates a negative outlook for Zimmer Biomet Holdings primarily due to anticipated revenue growth slowing to 2% or less, driven by underperforming ROSA robot sales and disappointing new product launches, leading to below-consensus earnings. Furthermore, the company faces significant headwinds from currency fluctuations and potential pricing pressures in the orthopedic implant market, with guidance for adjusted EPS falling short of consensus estimates. Additionally, risks related to slower orthopedic market growth, dilutive acquisitions, and new product performance add to the uncertainty surrounding the company's financial trajectory.
This aggregate rating is based on analysts' research of Zimmer Biomet Hlds and is not a guaranteed prediction by Public.com or investment advice.
ZBH Analyst Forecast & Price Prediction
Start investing in ZBH
Order type
Buy in
Order amount
Est. shares
0 shares